OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback